Update shared on04 Oct 2025
Fair value Decreased 0.56%Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations.
What's in the News
- Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle. This addresses a significant threat to U.S. livestock health (Key Developments).
- The Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion for Portela, a new monoclonal antibody therapy developed by Zoetis for osteoarthritis pain in cats. European Commission approval is anticipated in late 2025 (Key Developments).
- Zoetis completed significant fixed-income offerings totaling over $1.8 billion, with multiple financial institutions added as co-lead underwriters during recent transactions (Key Developments).
- The company has repurchased 2,139,606 shares from April to June 2025, representing 0.48% of shares, as part of its ongoing share buyback program (Key Developments).
- Zoetis raised its full-year 2025 earnings guidance, now expecting up to $9.6 billion in revenue and up to $6.00 in reported diluted earnings per share (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Reduced slightly from $190.29 to $189.22.
- Discount Rate: Remains unchanged at 6.78%.
- Revenue Growth: Expected growth rate has decreased marginally from 5.18% to 5.13%.
- Net Profit Margin: Narrowed slightly from 29.71% to 29.59%.
- Future P/E: Essentially flat, with 29.99x previously and 29.99x currently.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.